IC-MARKETS
4.11.2021 11:21:10 CET | Business Wire | Press release
IC Markets, one of the world’s largest Forex CFD broker, has secured the sponsorship of 12 football teams across Spain’s La Liga and Germany’s Bundesliga professional leagues, in the current 2021/22 season.
La Liga and Bundesliga are two of the most popular professional sports leagues globally and among Europe’s most elite football leagues, giving IC Markets access to an average attendance upwards of 25,000 for La Liga and 40,000 for Bundesliga games.
The La Liga teams included in the sponsorship deal are RCD Mallorca, Cadiz, Real Sociedad, Athletic Club Bilbao, Getafe and Granada. In the Bundesliga, IC Markets has secured sponsorships with Bayer 04 Leverkusen, Hertha BSC, FC Augsburg, DSC Arminia Bielefeld, Greuther Fürth and VfL Bochum.
Under the sponsorship terms, the IC Markets brand will gain exposure to live and broadcast audiences through branded LED displays on the teams’ home grounds, logo and IP rights, as well as access to VIP experiences and merchandise. The partnerships were facilitated by the global sport business agency SPORTFIVE.
IC Markets CEO Andrew Budzinski said the company was pleased to have secured the sponsorship rights to two of Europe’s leading football leagues.
"Practice, hard work and discipline are the foundations for success, and these values are in abundance in European football. The Bundesliga and La Liga stand out as leading examples of the virtues of sportsmanship, and IC Markets is proud to be taking this step with a league with such a rich legacy. La Liga and Bundesliga have deep roots in their communities, and this reflects in the loyalty shown by their fanbase. That's why we are partnering with these exceptional clubs to bring fans closer to the action than ever before," commented Mr Budzinski.
About IC Markets
Built by traders for traders, IC Markets is the world’s largest Forex CFD broker dedicated to offering exemptional trading conditions and world class 24/7 service to clients in over 200 countries around the world.
Since its launch in 2007, IC Markets has bridged the gap between retail and institutional clients, by offering a trading solution previously only available to investment banks and high net worth individuals.
As a result, IC Markets is the destination of choice for active traders worldwide who are seeking a trading environment that supports them to become a more confident and capable traders, delivering intuitive trading platforms with value-added tools and support for all trading strategies and styles.
IC Markets is dedicated to innovation, constant improvement, and utilising cutting edge technology for the benefit for our clients.
For more information click here .
Disclaimer:
CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 73.59% of retail investor accounts lose money when trading CFDs with this provider . You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
IC Markets (EU) Ltd is authorized and regulated by the Cyprus Securities and Exchange Commission with License No. 362/18
IC Markets (EU) Ltd is deemed authorised and regulated by the Financial Conduct Authority. The nature and extent of consumer protections may differ from those for firms based in the UK. Details of the Temporary Permissions Regime, which allows EEA-based firms to operate in the UK for a limited period while seeking full authorisation, are available on the Financial Conduct Authority’s website.
Cryptocurrency CFDs are not available to UK Retail Clients.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211104005564/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Alsym Energy Announces Na-Series Battery Success Developed With Physics-Informed AI Platform27.4.2026 21:25:00 CEST | Press release
Alsym’s proprietary physics-informed AI platform powered the development of its Na-Series batteries—a non-flammable, high performance and low cost energy solution positioned to serve critical energy storage markets including data centers, utilities, telecommunications, commercial real estate, industrial and defense, among others. Alsym Energy, a pioneer in non-flammable, high-performance sodium-ion batteries, today announced details of the proprietary physics-informed AI platform used to develop the company’s recently launched Na-Series sodium-ion batteries. By integrating fundamental physics models with AI, autonomous testing and proprietary molecular diagnostics in a closed-loop system, Alsym is accelerating the design of safer, inexpensive, commercialized batteries through all phases of the development cycle. As global demand for electricity surges, the limitations of lithium-ion batteries have become increasingly apparent, particularly around safety and supply chain constraints. Li
Backed by Investments Exceeding $1 Billion, PCI Pharma Services Announces Major Expansion of US Sterile Fill-Finish and Drug-Device Delivery Combination Capabilities27.4.2026 16:00:00 CEST | Press release
As pharma manufacturers prioritize US supply chain resilience, highlights include high-speed isolator filling lines for prefilled syringes, cartridges and vials, and drug-device combination assembly and packaging. PCI Pharma Services (“PCI”) – a world-leading integrated global contract development and manufacturing organization (CDMO) focused on innovative biologic and small molecule therapies – announced a series of major infrastructure investments that substantially deepen its sterile fill-finish and advanced drug delivery capabilities. As pharma manufacturers and their development partners increasingly prioritize US supply chain resilience, PCI’s latest investments come as part of a broader commitment exceeding $1 billion across the CDMO’s US and European operations, reinforcing its ability to provide seamless support for drug product development and manufacturing, clinical trial supply and drug-device combination assembly from clinical stages through commercial launch – all underpi
Pure Lithium Appoints Renowned Battery Expert Dr. Yuan Gao to Board of Directors27.4.2026 15:53:00 CEST | Press release
Pure Lithium Corporation, a vertically integrated lithium metal battery technology company, is pleased to announce that world-renowned inventor and battery expert Dr. Yuan Gao has joined the company’s Board of Directors. Dr. Gao has been an invaluable member of Pure Lithium’s Scientific Advisory Board since October of 2023. "We are thrilled to have Dr. Gao join our board as we focus on rapidly scaling our technology in the most capital efficient manner possible,” said Pure Lithium Founder, Chairman and CEO Emilie Bodoin. “Dr. Gao is a brilliant scientist who also has deep commercial expertise, a rare combination. He is also unique in the industry because his experience spans the entire battery materials value chain, including all of Pure Lithium’s verticals. His insights over the years have been critical in advancing our technology, and his experience as a director of public companies will strengthen our board.” Dr. Gao commented: “I am thrilled to join the board of Pure Lithium Corpor
Taiho Oncology, Taiho Pharmaceutical and Araris Biotech AG Advance ADC ARC-02 into Phase 1 Clinical Development27.4.2026 15:00:00 CEST | Press release
Phase 1 dose-escalation trial represents the first clinical trial of a product developed using the AraLinQ™ ADC technology and marks Taiho’s expansion into the clinical development of ADCs for oncology Taiho Oncology, Inc., Taiho Pharmaceutical Co., Ltd., and Araris Biotech AG (“Araris”) today announced that the U.S. Food and Drug Administration (FDA) has completed its Investigational New Drug (IND) review period for ARC-02, an antibody-drug conjugate (ADC) being developed for the treatment of non-Hodgkin lymphoma, enabling Taiho Oncology to initiate a Phase 1 dose-escalation clinical trial of ARC-02. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260427127507/en/ Taiho Pharmaceutical acquired Araris Biotech in March 2025, expanding Taiho group’s capabilities in biologics and ADC research and development. Araris is a spin-off of the Paul Scherrer Institute and ETH in Switzerland focused on the development of antibody-drug co
Boomi To Unveil the Future Of Data Activation and AI-Driven Innovation at Boomi World 202627.4.2026 15:00:00 CEST | Press release
Premier global event to highlight how organizations are bringing data to life to power everything from AI to BI Boomi, the data activation company, today announced Boomi World 2026, its premier annual user conference, taking place May 11 - 14, 2026 in Chicago, IL. The event will bring together customers, partners, and industry leaders from around the world to explore how data activation is transforming the enterprise and accelerating the path to AI-driven outcomes. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260427600340/en/ Boomi To Unveil the Future Of Data Activation and AI-Driven Innovation at Boomi World 2026 Boomi World 2026 will spotlight data activation — bringing data to life to power AI, analytics, and intelligent automation. Attendees will gain firsthand insights into how the Boomi Enterprise Platform enables businesses to unify data, streamline operations, and innovate faster in an increasingly agentic world.
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom